phase

Azentio appoints Harikrishnan Venkataramanan as President – ERP to spearhead next phase of innovation and growth

SINGAPORE, July 3, 2025 /PRNewswire/ -- Azentio Software ("Azentio"), a leading technology enabler in the banking, financial services, insurance (BFSI),…

2 hours ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

23 hours ago

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…

1 week ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

1 week ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology…

2 weeks ago

Kane Biotech Provides Further Corporate Update

WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates…

2 weeks ago

Infomerics Appoints Shubham Jain as Group CEO of Infomerics Ratings

NEW DELHI, June 16, 2025 /PRNewswire/ -- Infomerics Valuation and Rating Ltd, a leading credit rating agency, has announced the…

2 weeks ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

2 weeks ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

2 weeks ago